24-hour IOP-lowering Effect of Brimonidine 0.1%

Study Identifier
MA-080806-2
CT.gov Identifier
NCT00457795
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • brimonidine 0.1% (Alphagan® P)
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    40 - 80 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * patients with open-angle glaucoma or ocular hypertension
    Exclusion Criteria:
    * allergy to brimonidine * inability to complete 24 hour stay for monitoring

    Protocol Summary

    This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

    Study Locations

    Location
    Status
    Location
    San Diego, California, United States
    Status
    Not applicable